-
Mashup Score: 2
In patients where antidrug antibodies were detected, remission was less likely to be reached and sustained, and infusion reaction or discontinuation of infliximab was more likely. Timely detection of antidrug antibodies by proactive therapeutic drug monitoring facilitated treatment decisions that reduced the negative consequences, both regarding infliximab effectiveness and safety. This highlights the role of proactive therapeutic drug monitoring in optimising infliximab therapy.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0
In patients where antidrug antibodies were detected, remission was less likely to be reached and sustained, and infusion reaction or discontinuation of infliximab was more likely. Timely detection of antidrug antibodies by proactive therapeutic drug monitoring facilitated treatment decisions that reduced the negative consequences, both regarding infliximab effectiveness and safety. This highlights the role of proactive therapeutic drug monitoring in optimising infliximab therapy.
Source: www.thelancet.comCategories: General Medicine News, RheumatologyTweet-
NEW RESEARCH—@mk_brun and colleagues assess the clinical consequences of #infliximab immunogenicity and the effect of proactive therapeutic drug monitoring in an exploratory analyses of the NOR-DRUM trials https://t.co/HKIOHLgDJd @siljews @REMEDY_center https://t.co/TDTGeK0mKe
-
-
Mashup Score: 0Systematic review of studies comparing infliximab and adalimumab in autoimmune uveitis - 11 month(s) ago
Objective This study aimed to review effectiveness studies comparing two biological anti-tumour necrosis factor agents, adalimumab (ADA) and infliximab (IFX), in the management of autoimmune uveitis. Methods A systematic search was conducted across PubMed, Scopus, Web of Science and Google Scholar from 2014 until February 2022. The search included the following keywords “Adalimumab”,…
Source: BMJ Open OphthalmologyCategories: Latest Headlines, OphthalmologyTweet-
📢 Calling ophthalmologists! Check out this study on #infliximab vs. #adalimumab in autoimmune uveitis. Discover comparative effectiveness and safety profiles. Read more https://t.co/FUI2UezZrc #UveitisStudy #OphthalmologyResearch 📚 https://t.co/zHODsMqyev
-
-
Mashup Score: 2More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13 - 12 month(s) ago
CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease. “In the past several years, there have been a number of formulations of infliximab that have met criteria for what is known as biosimilarity,”
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Subcutaneous maintenance therapy with an #infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe #Crohnsdisease. #DDW23 @NMH_SHanauerMD https://t.co/SYpUQSBi4D
-
-
Mashup Score: 0
During the study follow-up period, 74.5% of switchers and 51.3% of infliximab-naïve patients remained on ABP 710 treatment without a treatment gap.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
During the study follow-up period, 74.5% of switchers and 51.3% of infliximab-naïve patients remained on ABP 710 treatment without a treatment gap. #biosimilar #infliximab https://t.co/giK46AJcs2
-
-
Mashup Score: 0Infliximab Biosimilar Not Associated With Adverse Events in IBD - 1 year(s) ago
No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
ICYMI: No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an #infliximab #biosimilar and those who continued treatment on the originator. https://t.co/XXHxMFXPTn
-
-
Mashup Score: 0Infliximab Biosimilar Not Associated With Adverse Events in IBD - 1 year(s) ago
No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an infliximab biosimilar and those who continued treatment on the originator.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: No statistically significant differences in infusion reaction, serious reaction, or immunogenicity rates were identified between patients switching to an #infliximab #biosimilar and those who continued treatment on the originator. https://t.co/hF6OiGaF5d
-
-
Mashup Score: 0Non-Medical Switch to Infliximab Biosimilar Did Not Impact Remission in Young Patients - 1 year(s) ago
No statically significant differences in ESR, CRP, TNF levels, and albumin were observed pre- and post-switch from the infliximab originator to the biosimilar.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
No statically significant differences in ESR, CRP, TNF levels, and albumin were observed pre- and post-switch from the #infliximab originator to the #biosimilar. https://t.co/rRpaxyoj8r
-
-
Mashup Score: 0Switching Between Infliximab, Biosimilars Deemed Safe, Effective in Patients With IBD - 1 year(s) ago
Most patients remained on infliximab biosimilars during the follow-up period and the number of switches was not independently linked to infliximab persistence after adjusting for confounders.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Most patients remained on #infliximab #biosimilars during the follow-up period and the number of switches was not independently linked to infliximab persistence after adjusting for confounders. https://t.co/1H85MCZxlw https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0Infliximab Monotherapy, Combination Therapy Comparable Among Biologic-Naïve Patients With IBD - 1 year(s) ago
At week 54, there were no significant differences in patients achieving the target exposure (5 µg/mL) between those in the monotherapy cohort and those in the combination therapy cohort.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
At week 54, there were no significant differences in patients achieving the target exposure (5 µg/mL) between those in the monotherapy cohort and those in the combination therapy cohort. #Infliximab #IBD https://t.co/ZRNvk2GbNT
-
NEW RESEARCH—@mk_brun and colleagues assess the clinical consequences of #infliximab immunogenicity and the effect of proactive therapeutic drug monitoring in an exploratory analyses of the NOR-DRUM trials https://t.co/HKIOHLgDJd @siljews @REMEDY_center https://t.co/TDTGeK0mKe